Drug
Bacillus Calmette-Guerin
Bacillus Calmette-Guerin is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_3
3
75%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
3(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(1)
Detailed Status
unknown1
Active, not recruiting1
Completed1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 33 (100.0%)
Trials by Status
unknown125%
active_not_recruiting125%
completed125%
withdrawn125%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_3
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
NCT04165317
unknown
Machine Learning-Based Prediction of BCG Response in High-Risk Non-Muscle Invasive Bladder Cancer Patients
NCT05332353
withdrawnphase_3
First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC
NCT01284205
completedphase_3
Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer
NCT01442519
Clinical Trials (4)
Showing 4 of 4 trials
NCT04165317Phase 3
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
NCT05332353
Machine Learning-Based Prediction of BCG Response in High-Risk Non-Muscle Invasive Bladder Cancer Patients
NCT01284205Phase 3
First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC
NCT01442519Phase 3
Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4